PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS

• M. Breccia,
• A. Turkina,
• C. Boquimpani,
• C. Chuah,
• G. Sharf,
• P. Schuld,
• M. Hoch,
• J. Yssel,
• Y. Zhang,
• A. Hochhaus

Affiliations

M. Breccia

1 Division of Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, Sapienza University, Rome, Italy

A. Turkina

2 National Research Center for Hematology, Moscow, Russia

C. Boquimpani

3 HEMORIO, State Institute of Hematology Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil

C. Chuah

4 Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore

G. Sharf

5 Israeli CML Patients Organization, Netanya, Israel

P. Schuld

7 Novartis Pharma AG, Basel, Switzerland

M. Hoch

7 Novartis Pharma AG, Basel, Switzerland

J. Yssel

8 Novartis Ireland Limited, Dublin, Ireland

Y. Zhang

9 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

A. Hochhaus

10 Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany